SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said ...

A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, extending a slow debut complicated by coverage questions and doctor concerns. The ...

Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is ...

While Biogen’s pharma peers are hunting for late-stage assets with little risk, CEO Chris Viehbacher wants to bring in more early-stage medicines, arguing that there’s more shareholder value to be had ...

Biogen CEO Michel Vounatsos told CNBC he remains “confident” the company’s Alzheimer’s drug will receive FDA approval. The Cambridge, Mass.-based drugmaker halted two late-stage trials for the drug, ...

Biogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually. The drugmaker said Monday that ...

Biogen said it is discontinuing its controversial drug Aduhelm, so it can focus resources on other Alzheimer’s treatments that drive long-term growth. This includes shifting its priorities to its ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Since its approval in 2023, the ...

Discover why Biogen Inc.'s stock surged 15% in 2025, driven by Skyclarys sales. Explore its strong growth potential and ...

This is an excerpt from STAT, the health and medicine news site that’s a partner to the Globe. For a full version of this story and related coverage, visit STAT. SAN FRANCISCO — Biogen would like to ...

Running a biotech company means taking risks — deciding where to invest, for example, or what scientific targets to chase. However, the sector faces another kind of risk, with a new administration in ...